On December 11, Wanhua Chemical issued an announcement stating that on November 10, 2020, Shanghai Wanhua Keju Chemical Technology Development Co., Ltd. ("Shanghai Wanhua Keju"), a wholly-owned subsidiary of Wanhua Chemical, had 100% equity in Shandong. The Exchange Center and Yantai United Property Rights Exchange Service Co., Ltd. were listed. On December 8, 2020, Jiangxi Jimin Trust Group Co., Ltd. ("Jinmin Trust Group") delisted at a price of RMB 78,889,999 to acquire 100% equity of Shanghai Wanhua Keju.
According to the announcement, Shanghai Wanhua Keju was established on October 25, 2012 with a registered capital of 49,999.99 million yuan. It is engaged in technology transfer, technology development and technical services in the chemical industry, sales of chemical raw materials and products, and manpower through service outsourcing. Resource services, etc.
In the first seven months of 2019 and 2020, operating income was 42 million yuan and 17.5 million yuan; net profits were -4.18 million yuan and -8.05 million yuan. As of July 31, 2020, Shanghai Wanhua Keju has total assets of 660 million yuan, liabilities of 98.285 million yuan, and net assets of 562 million yuan. After adopting the asset-based method, Shanghai Wanhua Keju has an appraisal value of 730 million yuan, an appraised appreciation of 168 million yuan, and an appreciation rate of 29.96%.
It is reported that the book value of net assets of Shanghai Wanhua Keju as of July 31, 2020 is 562,296,500 yuan, the appraised value is 730,780,300 yuan, the appraised value-added is 168,483,800 yuan, the appreciation rate is 29.96%; the transaction price of the transaction target is 788.9999 million yuan, the transaction price is lower than the appraised value Compared with the premium of RMB 58.219 million, the premium rate is 7.97%. The company and Jimin Trust Group signed the "Property Transaction Contract" on December 11, 2020.
Jimin Trust Group is headquartered in Nanchang, China. It is one of the leading large modern pharmaceutical groups in China. It focuses on the research and development, production and sales of chemical drugs, biological preparations, modern Chinese medicines, and health care products. It has established drugs in Shanghai, Nanjing and New Jersey, USA The research institute has 10 pharmaceutical bases in Beijing, Jiangxi, Jiangsu, Zhejiang, and Jilin. In 2019, it was selected as the National Brand Project of Xinhua News Agency, and it has been ranked among the top ten of China's pharmaceutical industry for many years.
Main financial indicators: As of December 31, 2019, Jimin Trust Group's total assets were 16.41976 million yuan, net assets were 6865.08 million yuan, operating income for 2019 was 9043.52 million yuan, and net profit was 2.075.88 million yuan. The aforementioned financial data Has been audited.
Regarding this transfer, Wanhua Chemical stated that the transfer of the company is to further integrate Wanhua Chemical's overall resources, improve the efficiency of capital use, activate assets, and enhance the company's strategic deployment and actual business development needs.
